Display options
Cite
Schneeweiss A, Lux MP, Janni W, et al. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018;78(3):246-259doi: 10.1055/s-0044-101614.
Schneeweiss, A., Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F. A., Overkamp, F., Kolberg, H. C., Hadji, P., Tesch, H., Wöckel, A., Ettl, J., Lüftner, D., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Wallwiener, D., Brucker, S. Y., Schütz, F., Fasching, P. A., & Fehm, T. N. (2018). Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe und Frauenheilkunde, 78(3), 246-259. https://doi.org/10.1055/s-0044-101614
Schneeweiss, Andreas, et al. "Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention." Geburtshilfe und Frauenheilkunde vol. 78,3 (2018): 246-259. doi: https://doi.org/10.1055/s-0044-101614
Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21. PMID: 29576630; PMCID: PMC5862553.
Copy Download .nbib Format: NLM
Share it on

Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.

Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.

Geburtshilfe und Frauenheilkunde

Andreas Schneeweiss, Michael P Lux, Wolfgang Janni, Andreas D Hartkopf, Naiba Nabieva, Florin-Andrei Taran, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Achim Wöckel, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Diethelm Wallwiener, Sara Y Brucker, Florian Schütz, Peter A Fasching, Tanja N Fehm

Affiliations

  1. National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital Heidelberg, Heidelberg, Germany.
  2. Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
  3. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  4. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.
  5. Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany.
  6. OncoConsult Hamburg GmbH, Hamburg, Germany.
  7. Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
  8. Department of Bone Oncology, Nordwest Hospital, Frankfurt, Germany.
  9. Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany.
  10. Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany.
  11. Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  12. Charité University Hospital, Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin, Germany.
  13. Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany.
  14. ClinSol GmbH & Co KG, Würzburg, Germany.
  15. Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.

PMID: 29576630 PMCID: PMC5862553 DOI: 10.1055/s-0044-101614

Abstract

The treatment of metastatic breast cancer has become more complicated due to increasing numbers of new therapies which need to be tested. Therapies are now being developed to treat special clinical or molecular subgroups. Even though intrinsic molecular subtypes play a major role, more and more new therapies for subgroups and histological subtypes are being developed, such as the use of PARP inhibitors to treat patients with BRCA mutations (breast and ovarian cancer). Supportive therapies are also evolving, allowing problems such as alopecia or nausea and vomiting to be treated more effectively. Treatment-related side effects have a direct impact on the prognosis of patients with metastatic breast cancer, and supportive therapy can improve compliance. Digital tools could be useful to establish better patient management systems. This overview provides an insight into recent trials and how the findings could affect routine treatment. Current aspects of breast cancer prevention are also presented.

Keywords: CDK4/6; PD1/PDL1; breast cancer; metastasis; prevention; risk; treatment; trials

References

  1. J Clin Oncol. 2016 Aug 10;34(23 ):2750-60 - PubMed
  2. Oncotarget. 2017 Jan 17;8(3):3811-3825 - PubMed
  3. Geburtshilfe Frauenheilkd. 2013 Dec;73(12):1228-1235 - PubMed
  4. J Natl Cancer Inst. 2015 Apr 08;107(5):null - PubMed
  5. JAMA Oncol. 2017 Sep 1;3(9):1190-1196 - PubMed
  6. PLoS One. 2016 May 05;11(5):e0153788 - PubMed
  7. Cell Res. 2016 Jul;26(7):761-74 - PubMed
  8. Breast Cancer Res Treat. 2013 Feb;138(1):185-91 - PubMed
  9. JMIR Cancer. 2017 Aug 07;3(2):e11 - PubMed
  10. J Natl Cancer Inst. 2015 Mar 04;107(5):null - PubMed
  11. Breast Cancer Res Treat. 2013 Jun;139(2):429-40 - PubMed
  12. J Med Internet Res. 2017 Sep 14;19(9):e322 - PubMed
  13. Geburtshilfe Frauenheilkd. 2017 Jun;77(6):667-678 - PubMed
  14. J Clin Oncol. 2016 Jul 20;34(21):2452-9 - PubMed
  15. J Med Genet. 2016 Dec;53(12 ):800-811 - PubMed
  16. Cancer Res. 2017 Jun 1;77(11):2789-2799 - PubMed
  17. Breast Cancer Res Treat. 2012 Oct;135(3):811-20 - PubMed
  18. Int J Epidemiol. 2018 Jan 5;:null - PubMed
  19. Biomed Res Int. 2014;2014:842452 - PubMed
  20. Geburtshilfe Frauenheilkd. 2011 Dec;71(12):1056-1066 - PubMed
  21. J Natl Cancer Inst. 2015 Aug 20;107(11): - PubMed
  22. Cancer Res. 2012 Apr 1;72(7):1795-803 - PubMed
  23. Geburtshilfe Frauenheilkd. 2015 Jan;75(1):41-50 - PubMed
  24. Lancet. 2015 Oct 3;386(10001):1353-1361 - PubMed
  25. Curr Opin Obstet Gynecol. 2017 Feb;29(1):4-11 - PubMed
  26. Nat Med. 2016 Aug;22(8):933-9 - PubMed
  27. Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1156-66 - PubMed
  28. JAMA. 2017 Jul 11;318(2):197-198 - PubMed
  29. N Engl J Med. 2017 Aug 10;377(6):523-533 - PubMed
  30. Nature. 2017 Nov 2;551(7678):92-94 - PubMed
  31. Ann Oncol. 2013 Jun;24(6):1505-12 - PubMed
  32. Ann Oncol. 2018 Jan 1;29(1):186-192 - PubMed
  33. Int J Epidemiol. 2017 Dec 1;46(6):1814-1822 - PubMed
  34. Transl Oncol. 2017 Aug;10 (4):589-598 - PubMed
  35. J Clin Oncol. 2016 Jul 20;34(21):2460-7 - PubMed
  36. Breast. 2018 Feb;37:154-160 - PubMed
  37. Breast Cancer Res Treat. 2013 Dec;142(3):603-9 - PubMed
  38. Ann Oncol. 2014 Feb;25(2):372-7 - PubMed
  39. Geburtshilfe Frauenheilkd. 2017 Aug;77(8):870-878 - PubMed
  40. Am J Hum Genet. 2016 Oct 6;99(4):903-911 - PubMed
  41. Carcinogenesis. 2014 May;35(5):1012-9 - PubMed
  42. Nat Genet. 2017 Dec;49(12 ):1767-1778 - PubMed
  43. Nat Commun. 2016 Apr 27;7:11375 - PubMed
  44. J Clin Oncol. 2015 Feb 1;33(4):304-11 - PubMed

Publication Types